These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 30200781)

  • 1. Efficacy and safety of tapentadol prolonged release formulation in the treatment of elderly patients with moderate-to-severe chronic osteoarthritis knee pain: a pooled analysis of two double-blind, randomized, placebo-, and active-controlled trials.
    Lange B; Sohns M; Tempero J; Elling C
    Curr Med Res Opin; 2018 Dec; 34(12):2113-2123. PubMed ID: 30200781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of tapentadol prolonged release for moderate-to-severe chronic osteoarthritis knee pain: a pooled analysis of two double-blind, randomized, placebo- and oxycodone controlled release-controlled studies.
    Lange B; von Zabern D; Elling C; Dubois C
    Curr Med Res Opin; 2017 Aug; 33(8):1413-1422. PubMed ID: 28537506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tapentadol prolonged-release for moderate-to-severe chronic osteoarthritis knee pain: a double-blind, randomized, placebo- and oxycodone controlled release-controlled study.
    Serrie A; Lange B; Steup A
    Curr Med Res Opin; 2017 Aug; 33(8):1423-1432. PubMed ID: 28537501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability and efficacy of tapentadol extended release in elderly patients ≥ 75 years of age with chronic osteoarthritis knee or low back pain.
    Biondi DM; Xiang J; Etropolski M; Moskovitz B
    J Opioid Manag; 2015; 11(5):393-403. PubMed ID: 26535967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and tolerability of tapentadol extended release in moderate to severe chronic osteoarthritis or low back pain management: pooled analysis of randomized controlled trials.
    Etropolski M; Kuperwasser B; Flügel M; Häufel T; Lange B; Rauschkolb C; Laschewski F
    Adv Ther; 2014 Jun; 31(6):604-20. PubMed ID: 24985410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study.
    Hartrick C; Van Hove I; Stegmann JU; Oh C; Upmalis D
    Clin Ther; 2009 Feb; 31(2):260-71. PubMed ID: 19302899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study.
    Afilalo M; Etropolski MS; Kuperwasser B; Kelly K; Okamoto A; Van Hove I; Steup A; Lange B; Rauschkolb C; Haeussler J
    Clin Drug Investig; 2010; 30(8):489-505. PubMed ID: 20586515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain.
    Kress HG; Koch ED; Kosturski H; Steup A; Karcher K; Lange B; Dogan C; Etropolski MS; Eerdekens M
    Pain Physician; 2014; 17(4):329-43. PubMed ID: 25054392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tapentadol for chronic musculoskeletal pain in adults.
    Santos J; Alarcão J; Fareleira F; Vaz-Carneiro A; Costa J
    Cochrane Database Syst Rev; 2015 May; 2015(5):CD009923. PubMed ID: 26017279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term Safety and Efficacy of Tapentadol Extended Release Following up to 2 Years of Treatment in Patients With Moderate to Severe, Chronic Pain: Results of an Open-label Extension Trial.
    Buynak R; Rappaport SA; Rod K; Arsenault P; Heisig F; Rauschkolb C; Etropolski M
    Clin Ther; 2015 Nov; 37(11):2420-38. PubMed ID: 26428249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of prolonged-release oxycodone/naloxone on outcomes affecting patients' daily functioning in comparison with extended-release tapentadol: a systematic review.
    Thakur D; Dickerson S; Kumar Bhutani M; Junor R
    Clin Ther; 2015 Jan; 37(1):212-24. PubMed ID: 25592091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of tapentadol ER for managing moderate to severe chronic pain.
    Afilalo M; Morlion B
    Pain Physician; 2013 Jan; 16(1):27-40. PubMed ID: 23340531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Composite measure to assess efficacy/gastrointestinal tolerability of tapentadol ER versus oxycodone CR for chronic pain: pooled analysis of randomized studies.
    Merchant S; Provenzano D; Mody S; Ho KF; Etropolski M
    J Opioid Manag; 2013; 9(1):51-61. PubMed ID: 23709304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-label, Phase 3b/4 Trial.
    Baron R; Jansen JP; Binder A; Pombo-Suarez M; Kennes L; Müller M; Falke D; Steigerwald I
    Pain Pract; 2016 Jun; 16(5):600-19. PubMed ID: 26554630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness and tolerability of tapentadol prolonged release compared with prior opioid therapy for the management of severe, chronic osteoarthritis pain.
    Steigerwald I; Schenk M; Lahne U; Gebuhr P; Falke D; Hoggart B
    Clin Drug Investig; 2013 Sep; 33(9):607-19. PubMed ID: 23912473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study.
    Hale M; Upmalis D; Okamoto A; Lange C; Rauschkolb C
    Curr Med Res Opin; 2009 May; 25(5):1095-104. PubMed ID: 19301989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study.
    Buynak R; Shapiro DY; Okamoto A; Van Hove I; Rauschkolb C; Steup A; Lange B; Lange C; Etropolski M
    Expert Opin Pharmacother; 2010 Aug; 11(11):1787-804. PubMed ID: 20578811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes Associated with Treatment of Chronic Pain with Tapentadol Compared with Morphine and Oxycodone: A UK Primary Care Observational Study.
    Morgan CL; Jenkins-Jones S; Currie C; Baxter G
    Adv Ther; 2019 Jun; 36(6):1412-1425. PubMed ID: 30963513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.
    Hale M; Tudor IC; Khanna S; Thipphawong J
    Clin Ther; 2007 May; 29(5):874-888. PubMed ID: 17697906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post hoc analyses of data from a 90-day clinical trial evaluating the tolerability and efficacy of tapentadol immediate release and oxycodone immediate release for the relief of moderate to severe pain in elderly and nonelderly patients.
    Vorsanger G; Xiang J; Biondi D; Upmalis D; Delfgaauw J; Allard R; Moskovitz B
    Pain Res Manag; 2011; 16(4):245-51. PubMed ID: 22059194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.